BG102784A - Synthetic hiv genes - Google Patents

Synthetic hiv genes

Info

Publication number
BG102784A
BG102784A BG102784A BG10278498A BG102784A BG 102784 A BG102784 A BG 102784A BG 102784 A BG102784 A BG 102784A BG 10278498 A BG10278498 A BG 10278498A BG 102784 A BG102784 A BG 102784A
Authority
BG
Bulgaria
Prior art keywords
synthetic
hiv genes
synthetic hiv
codons
genes
Prior art date
Application number
BG102784A
Other languages
Bulgarian (bg)
English (en)
Inventor
John SHIVER
Mary-Ellen Davies
Daniel FREED
Margaret Liu
Helen PERRY
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9607293.9A external-priority patent/GB9607293D0/en
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of BG102784A publication Critical patent/BG102784A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BG102784A 1996-02-22 1998-09-23 Synthetic hiv genes BG102784A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1208296P 1996-02-22 1996-02-22
GBGB9607293.9A GB9607293D0 (en) 1996-04-09 1996-04-09 Synthetic hiv env genes
PCT/US1997/002294 WO1997031115A2 (en) 1996-02-22 1997-02-18 Synthetic hiv genes

Publications (1)

Publication Number Publication Date
BG102784A true BG102784A (en) 1999-05-31

Family

ID=26309076

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102784A BG102784A (en) 1996-02-22 1998-09-23 Synthetic hiv genes

Country Status (27)

Country Link
EP (1) EP0904380B1 (xx)
JP (1) JP2000505299A (xx)
KR (1) KR19990087126A (xx)
CN (1) CN1216064A (xx)
AR (1) AR005930A1 (xx)
AT (1) ATE309366T1 (xx)
AU (1) AU729231B2 (xx)
BG (1) BG102784A (xx)
BR (1) BR9707672A (xx)
CO (1) CO4600706A1 (xx)
CZ (1) CZ266798A3 (xx)
DE (1) DE69734585T2 (xx)
EE (1) EE9800257A (xx)
ES (1) ES2251734T3 (xx)
HR (1) HRP970092A2 (xx)
HU (1) HUP9901112A3 (xx)
ID (1) ID16021A (xx)
IL (1) IL125547A0 (xx)
IS (1) IS4814A (xx)
NO (1) NO983876L (xx)
NZ (1) NZ331161A (xx)
PE (1) PE43298A1 (xx)
PL (1) PL328730A1 (xx)
SK (1) SK112998A3 (xx)
TR (1) TR199801615T2 (xx)
WO (1) WO1997031115A2 (xx)
YU (1) YU35498A (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
CA2258568A1 (en) * 1996-06-21 1997-12-24 Merck & Co., Inc. Vaccines comprising synthetic genes
EE9900343A (et) * 1997-02-07 2000-02-15 Merck & Co., Inc. Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
US6696291B2 (en) 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
US7105724B2 (en) 1997-04-04 2006-09-12 Board Of Regents Of University Of Nebraska Methods and materials for making and using transgenic dicamba-degrading organisms
KR100558838B1 (ko) 1997-04-04 2006-03-10 보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카 유전자이식 디캄바-분해 유기체를 제조하고 사용하기 위한 방법 및 물질
AU2003200914B2 (en) * 1997-10-20 2007-02-01 Gtc Biotherapeutics, Inc. Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems
CN1179048C (zh) * 1997-10-20 2004-12-08 Gtc生物治疗学公司 修饰的MSP-1核酸序列以及增加细胞系统中mRNA水平和蛋白质表达的方法
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
JP2002533124A (ja) * 1998-12-31 2002-10-08 カイロン コーポレイション Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成
EP1433851A3 (en) * 1998-12-31 2004-10-13 Chiron Corporation Improved expression of HIV polypeptides and production of virus-like particles
EP1535995A1 (en) * 1998-12-31 2005-06-01 Chiron Corporation Polynucleotides encoding the antigenic HIV type C env polypeptide and uses thereof
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2358385C (en) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US6395714B1 (en) 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
WO2000029561A2 (en) 1999-03-29 2000-05-25 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
CA2378539A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
US6316253B1 (en) 1999-11-01 2001-11-13 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
AU779951B2 (en) * 1999-12-22 2005-02-24 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized HIV-1 pol and modified HIV-1 pol
GB0014288D0 (en) 2000-06-10 2000-08-02 Smithkline Beecham Biolog Vaccine
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
CA2425152A1 (en) * 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
KR20020059856A (ko) 2001-01-08 2002-07-16 김철중 에이치아이브이 유사입자의 제조
EP1411770A4 (en) 2001-07-05 2006-05-10 Chiron Corp POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE
EP1427826B1 (en) * 2001-09-20 2011-04-20 Glaxo Group Limited HIV- RT-nef-Gag codon optimised DNA vaccines
ATE554106T1 (de) 2003-12-23 2012-05-15 Arbor Vita Corp Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
US7855326B2 (en) 2006-06-06 2010-12-21 Monsanto Technology Llc Methods for weed control using plants having dicamba-degrading enzymatic activity
EA020590B1 (ru) 2006-10-16 2014-12-30 Монсанто Текнолоджи Ллс Способы улучшения жизнеспособности растений
US7838729B2 (en) 2007-02-26 2010-11-23 Monsanto Technology Llc Chloroplast transit peptides for efficient targeting of DMO and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434469T2 (de) * 1993-01-26 2006-06-14 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
CA2181832C (en) * 1994-01-27 2012-11-27 Harriet L. Robinson Immunization by inoculation of dna transcription unit
US6630455B1 (en) * 1995-01-13 2003-10-07 Vanderbilt University Methods for inducing mucosal immune responses
JPH08198774A (ja) * 1995-01-20 1996-08-06 Terumo Corp Ｄｎａワクチン

Also Published As

Publication number Publication date
AU729231B2 (en) 2001-01-25
WO1997031115A2 (en) 1997-08-28
NO983876L (no) 1998-10-21
HRP970092A2 (en) 1998-04-30
AR005930A1 (es) 1999-07-21
NO983876D0 (no) 1998-08-21
DE69734585D1 (de) 2005-12-15
AU2124697A (en) 1997-09-10
HUP9901112A2 (hu) 1999-07-28
DE69734585T2 (de) 2006-08-10
NZ331161A (en) 2000-03-27
JP2000505299A (ja) 2000-05-09
YU35498A (sh) 1999-07-28
EE9800257A (et) 1999-02-15
ATE309366T1 (de) 2005-11-15
IS4814A (is) 1998-07-30
CN1216064A (zh) 1999-05-05
EP0904380A2 (en) 1999-03-31
PL328730A1 (en) 1999-02-15
HUP9901112A3 (en) 2001-06-28
EP0904380B1 (en) 2005-11-09
KR19990087126A (ko) 1999-12-15
CZ266798A3 (cs) 1999-03-17
ES2251734T3 (es) 2006-05-01
TR199801615T2 (xx) 1998-11-23
PE43298A1 (es) 1998-08-29
IL125547A0 (en) 1999-03-12
CO4600706A1 (es) 1998-05-08
WO1997031115A3 (en) 1997-10-09
SK112998A3 (en) 2000-04-10
BR9707672A (pt) 1999-04-13
ID16021A (id) 1997-08-28

Similar Documents

Publication Publication Date Title
BG102784A (en) Synthetic hiv genes
MX9701497A (es) Polimeros de ioneno que contienen aniones biologicamente activos.
DE69534778D1 (en) Cathepsin-02-protease
BR9814404A (pt) " clonagem de expressão em fungos filamentosos "
IL131131A0 (en) Synthetic hiv gag genes
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
DK1009832T3 (da) Cytokin betegnet LERK-6
PT1212358E (pt) Genes sinteticos de papilomavirus humano
CA2278028A1 (en) Methods for improving transformation efficiency
WO1999004011A3 (en) Hiv-1 group o antigens and uses thereof
FI971276A (fi) Lerk-6:ksi nimetty sytokiini
DE69726160D1 (de) Neue polymerisierbare acylimidazolidinonmonomere
AU3711597A (en) A novel galanin receptor
CA2287902A1 (en) Isolated nucleic acid molecules encoding ssx family members and uses thereof
PL329353A1 (en) Novel indications for application of as a drug the agents obtained from smallpox or parapox viruses, possessing many potential ablities, capable to produce parapox immunity
EP0237676A3 (en) Recombinant ricin toxin
PT870015E (pt) Novas xilanases os genes que as codificam e as suas utilizacoes
WO2001039786A3 (en) New uses of suppressive macrophage activation factors
DE69838615D1 (de) ppGpp-SYNTHETASE UND EXPRESSIONSSYSTEME ZUR VERBESSERTEN HERSTELLUNG VON PROTEINEN
WO2001070808A3 (en) Angiogenesis - associated proteins, and nucleic acids encoding the same
ZA99445B (en) Isolated, polypeptides which bind to HLA-A29 molecules nucleic acid, the molecules encoding these, and uses thereof.
SE9604439D0 (sv) New receptor
Wohlman Plato's Invisible Cities
EA199900726A1 (ru) Синтетические hiv gag гены
IT8520282A0 (it) Procedimento per migliorare le proprieta' del cemento, e cemento cosi' ottenuto.